Table 2.

Early vs delayed ASCT

Ref.YearStudy typeInduction regimen (early ASCT vs delayed ASCT)Response (early vs delayed ASCT)PFS (early vs delayed ASCT)OS (early vs delayed ASCT)
Fermand et al13  1998 VAMP × 3-4 cycles and ASCT vs VMCP until plateau and ASCT at relapse 85.7% vs 55.5% 39 mo vs 13 mo 64.6 mo vs 64 mo (P = .92) 
Attal et al16  2017 VRD × 3 cycles and ASCT + VRD × 2 cycles vs VRD × 8 cycles and ASCT at relapse CR: 59% vs 48% (P = .03) 50 mo vs 36 mo (P < .01) 4 y: 81% vs 82% 
Kumar et al24  2012 TD or RD × 4-6 cycles followed by early or delayed ASCT  20 mo vs 16 mo (P = NS) 4 y: 73% vs 73% (P = .3) 
Dunavin et al23  2013 T-, R-, or V-based induction followed by early or delayed ASCT ≥VGPR: 77% vs 55% (P < .01) 28 mo vs 18 mo (P = .11) NR vs 83 mo (P = .45) 
Remenyi et al25  2016 57% in early ASCT and 53.2% in delayed ASCT group received novel therapies CR: 58.1% vs 46.8% (P = .016) 30.2 mo vs 23.3 mo (P = .036) 97.2 mo vs 99.1 mo (P = .77) 
Ref.YearStudy typeInduction regimen (early ASCT vs delayed ASCT)Response (early vs delayed ASCT)PFS (early vs delayed ASCT)OS (early vs delayed ASCT)
Fermand et al13  1998 VAMP × 3-4 cycles and ASCT vs VMCP until plateau and ASCT at relapse 85.7% vs 55.5% 39 mo vs 13 mo 64.6 mo vs 64 mo (P = .92) 
Attal et al16  2017 VRD × 3 cycles and ASCT + VRD × 2 cycles vs VRD × 8 cycles and ASCT at relapse CR: 59% vs 48% (P = .03) 50 mo vs 36 mo (P < .01) 4 y: 81% vs 82% 
Kumar et al24  2012 TD or RD × 4-6 cycles followed by early or delayed ASCT  20 mo vs 16 mo (P = NS) 4 y: 73% vs 73% (P = .3) 
Dunavin et al23  2013 T-, R-, or V-based induction followed by early or delayed ASCT ≥VGPR: 77% vs 55% (P < .01) 28 mo vs 18 mo (P = .11) NR vs 83 mo (P = .45) 
Remenyi et al25  2016 57% in early ASCT and 53.2% in delayed ASCT group received novel therapies CR: 58.1% vs 46.8% (P = .016) 30.2 mo vs 23.3 mo (P = .036) 97.2 mo vs 99.1 mo (P = .77) 

CR, complete response; NR, not reached; NS, nonsignificant; P, prospective; r, retrospective; R, Revlimid; RD, Revlimid, dexamethasone; Ref., reference; T, thalidomide; TD, thalidomide, dexamethasone; V, Velcade; VAMP, vincristine, Adriamycin, melphalan, prednisolone; VGPR, very good partial response; VMCP, vincristine, melphalan, cyclophosphamide, prednisolone; VRD, Velcade, Revlimid, dexamethasone.

or Create an Account

Close Modal
Close Modal